NK cells restrain cytotoxic CD8 + T cells in the submandibular gland via PD-1-PD-L1.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101688624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2470-9468 (Electronic) Linking ISSN: 24709468 NLM ISO Abbreviation: Sci Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : American Association for the Advancement of Science, [2016]-
    • Subject Terms:
      Programmed Cell Death 1 Receptor*/immunology ; Killer Cells, Natural*/immunology ; B7-H1 Antigen*/immunology ; CD8-Positive T-Lymphocytes*/immunology ; Submandibular Gland*/immunology ; Mice, Knockout*; Animals ; Mice ; Mice, Inbred C57BL ; Humans ; Female ; Sjogren's Syndrome/immunology
    • Abstract:
      The increasing use of anti-programmed cell death 1 (PD-1) immune checkpoint blockade has led to the emergence of immune-related adverse events (irAEs), including dysfunction of the submandibular gland (SMG). In this study, we investigated the immunoregulatory mechanism contributing to the susceptibility of the SMG to irAEs. We found that the SMGs of PD-1-deficient mice and anti-programmed cell death ligand 1 (PD-L1)-treated mice harbor an expanded population of CD8 + T cells. We demonstrate that natural killer (NK) cells expressing PD-L1 tightly regulate CD8 + T cells in the SMG. When this immunoregulation is disrupted, CD8 + T cells clonally expand and acquire a unique transcriptional profile consistent with T cell receptor (TCR) activation. These clonally expanded cells phenotypically overlapped with cytotoxic GzmK + CD8 + T autoimmune cells identified in patients with primary Sjögren's syndrome. Understanding how NK cells modulate CD8 + T cell activity in the SMG opens new avenues for preventing irAEs in patients undergoing checkpoint blockade therapies.
    • Accession Number:
      0 (Programmed Cell Death 1 Receptor)
      0 (B7-H1 Antigen)
      0 (Pdcd1 protein, mouse)
      0 (Cd274 protein, mouse)
    • Publication Date:
      Date Created: 20241220 Date Completed: 20241220 Latest Revision: 20241220
    • Publication Date:
      20241221
    • Accession Number:
      10.1126/sciimmunol.adl2967
    • Accession Number:
      39705335